Track topics on Twitter Track topics that are important to you
The European Commission (EC) has granted marketing authorisation for Bayer’s stivarga (regorafenib) used for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with nexavar (sorafenib).
Original Article: Bayer’s stivarga receives EU marketing approval for HCC treatmentNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...